Cresco Labs OTC Balances Strong Margins With Near-Term Strain

Cresco Labs OTC ((TSE:CL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Cresco Labs OTC’s latest earnings call painted a picture of a structurally stronger business balancing solid profitability with clear near-term pressures. Management highlighted expanding margins, consistent cash generation, and a fortified balance sheet, while also warning of softer revenue, wholesale declines, price compression, and one-off items that boosted Q4 margins but will not repeat.

Quarterly Revenue and Profitability

Cresco reported Q4 revenue of $162 million, with adjusted gross profit of $84 million and adjusted EBITDA of $40 million, underscoring a profitable quarter. Operating cash flow reached $27 million, reinforcing that the company is generating real cash from operations rather than relying on financing.

Full-Year Financial Results

For the full year, Cresco delivered $656 million in revenue and $157 million in adjusted EBITDA, showing resilient performance across a choppy industry backdrop. Operating cash flow of $73 million allowed the company to materially strengthen its balance sheet heading into 2025.

Margin Expansion

Adjusted gross margin climbed to 52.2% in Q4, up from 48.8% in Q3, a 3.4 percentage point improvement that reflects better mix and operational efficiency. Adjusted EBITDA margin also ticked higher to 25.0% of revenue from 24.1%, signaling that incremental revenue is increasingly dropping to the bottom line.

Balance Sheet and Liquidity Improvements

The company ended the year with $94 million in cash and no near-term debt maturities after pushing its obligations out to 2030. This improved liquidity profile gives Cresco more flexibility to navigate market volatility and selectively pursue growth opportunities without balance sheet strain.

Operational Execution and Cost Control

Management continued to enforce tight cost discipline, with adjusted SG&A at $49 million, or 30.5% of revenue, demonstrating solid expense leverage. The reduction in bad debt reserves in Q4 further supported profitability, while capex was kept modest at $9 million, underscoring a capital-light approach.

Retail and Wholesale Market Leadership

Cresco reinforced its leadership in key states, maintaining the #1 branded market share in Illinois, Pennsylvania, and Massachusetts, according to Headset. On the retail side, it holds leading positions in Illinois and is among the top players in Ohio and Pennsylvania, with its Sunnyside chain boasting a 4.9 average Google rating.

Digital and Loyalty Strength

Digital engagement remains a core differentiator, with over 500,000 loyalty members and roughly 75% of sales flowing through a digital gateway. This data-rich environment allows Cresco to fine-tune assortment, pricing, and promotions while lowering customer acquisition costs for new product launches.

Strategic Footprint Actions and International Pilot

The company exited California to reallocate capital to markets offering higher returns and more predictable economics. Internationally, a pilot in Germany sold out ahead of schedule, and management is reinvesting those profits to scale the opportunity in a measured, capital-light fashion.

M&A Pipeline and Strategic Options

Cresco described its M&A pipeline as robust, but stressed a disciplined approach focused on tuck-in deals that meet strict return and integration criteria. The goal is to build market density and operating leverage without overextending the balance sheet or diluting existing profitability.

Modest Revenue Softening and Wholesale Decline

Management acknowledged modest revenue softening in Q4, with wholesale revenues declining about 6% sequentially. The company has deliberately prioritized supplying its own retail stores over lower-margin wholesale, trading some top-line growth for healthier profitability.

Q1 Revenue Headwinds Expected

The company expects a high single-digit sequential revenue drop in Q1, driven mainly by Michigan excise tax changes and the previously announced exit from California. Normal seasonality and ongoing price compression will add to these pressures, keeping near-term growth subdued.

Margin Benefits Partly Non-Recurring

Q4 gross margin received a boost from favorable one-off items that are unlikely to repeat, and management signaled that margins should normalize from the unusually high level. Seasonal mix shifts and competitive pricing will also weigh on margins, moderating the pace of expansion seen in late 2024.

Competitive Pressure and Price Compression

Cresco continues to face intense competition and price compression across its core markets, which is limiting revenue growth and pressuring unit economics. Management pointed to intoxicating hemp products as a lower-priced substitute, noting that regulatory relief would be needed to restore meaningful pricing power.

New York Impairment and Structural Concerns

The company recorded an impairment charge related to its New York operations, citing structural challenges in that market. Those headwinds have muted Cresco’s appetite for deploying more capital there unless the regulatory and operating landscape shows clear signs of improvement.

One-Time Expense Levers May Not Repeat

Q4 expenses benefited from non-recurring factors, including a reduction in bad debt reserves that helped SG&A leverage. Management cautioned that such levers will not recur in Q1, limiting the scope for further near-term margin gains from cost-line surprises.

Short-Term Growth Tradeoffs From Footprint Optimization

The decision to exit California and reinvest in higher-return markets is expected to enhance long-term value creation but comes with near-term revenue tradeoffs. Management acknowledged transitional disruption as it rebalances its footprint, yet views this as a necessary step to sharpen focus on its strongest regions.

Forward-Looking Guidance and Outlook

Management guided to a high single-digit sequential decline in Q1 revenue from the Q4 base of $162 million, mainly due to Michigan tax changes and the California exit. They expect gross margin to step down from Q4’s elevated level and SG&A to stay roughly in line with recent trends, while emphasizing that Q1 is not a directional shift and that performance should build through 2026 as efficiencies, mix improvements, and disciplined M&A drive operating leverage.

Cresco Labs emerges from the earnings call as a cannabis operator with solid cash generation, rising margins, and reduced balance sheet risk, but also facing tangible near-term revenue and pricing pressures. For investors, the story is one of a more resilient platform making strategic tradeoffs today, with management betting that tight discipline and targeted expansion will pay off in stronger growth and profitability over the next two years.